CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia

被引：0
|
作者：
Yao, Yao [1 ,2 ]
Zhou, Jin [1 ,2 ]
Li, Yanting [1 ,2 ]
Shi, Sensen [1 ,2 ]
Yu, Lei [3 ]
Wu, Depei [1 ,2 ]
Wang, Ying [1 ,2 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2024年
关键词：
YOUNG-ADULTS; CHILDREN;
D O I：
10.1007/s00277-024-05945-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6031 / 6033
页数：3
相关论文
共 50 条
  • [1] The first case of elderly TCF3-HLF-positive B-cell acute lymphoblastic leukemia
    Takeda, Reina
    Yokoyama, Kazuaki
    Ogawa, Miho
    Kawamata, Toyotaka
    Fukuyama, Tomofusa
    Kondoh, Kanya
    Takei, Tomomi
    Nakamura, Sousuke
    Ito, Mika
    Yusa, Nozomi
    Shimizu, Eigo
    Ohno, Nobuhiro
    Uchimaru, Kaoru
    Yamaguchi, Rui
    Imoto, Seiya
    Miyano, Satoru
    Tojo, Arinobu
    LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2821 - 2824
  • [2] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
  • [3] Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Zhang, Xian
    Yang, Junfang
    Li, Wenqian
    Zhang, Gailing
    Su, Yunchao
    Shi, Yanze
    Song, Dan
    Zhang, Min
    He, Jiujiang
    Xu, Li
    Li, Jingjing
    Lu, Xinan
    Li, Jianqiang
    Li, Xiangqun
    Xu, Zhongwei
    Li, Ziyu
    Lu, Peihua
    BLOOD, 2020, 136
  • [4] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
    Liu, Shuangyou
    Deng, Biping
    Yin, Zhichao
    Lin, Yuehui
    An, Lihong
    Liu, Dan
    Pan, Jing
    Yu, Xinjian
    Chen, Bingzhen
    Wu, Tong
    Chang, Alex H.
    Tong, Chunrong
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
  • [5] TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings
    Li, Meng-Ju
    Yu, Chih-Hsiang
    Chou, Shu-Wei
    Su, Ying-Hui
    Liao, Kuang-Wen
    Chang, Hsiu-Hao
    Yang, Yung-Li
    JCO PRECISION ONCOLOGY, 2022, 6
  • [6] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
    Jing Pan
    Qing Niu
    Biping Deng
    Shuangyou Liu
    Tong Wu
    Zhiyong Gao
    Zhaoli Liu
    Yue Zhang
    Xiaomin Qu
    Yanlei Zhang
    Shaohui Liu
    Zhuojun Ling
    Yuehui Lin
    Yongqiang Zhao
    Yanzhi Song
    Xiyou Tan
    Yan Zhang
    Zhihui Li
    Zhichao Yin
    Bingzhen Chen
    Xinjian Yu
    Ju Yan
    Qinlong Zheng
    Xuan Zhou
    Jin Gao
    Alex H. Chang
    Xiaoming Feng
    Chunrong Tong
    Leukemia, 2019, 33 : 2854 - 2866
  • [7] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
    Jing, P.
    Niu, Q.
    Deng, B.
    Liu, S.
    Wu, T.
    Gao, Z.
    Chang, A. H.
    Feng, X.
    Tong, C.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1723 - 1723
  • [8] CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
    Pan, Jing
    Niu, Qing
    Deng, Biping
    Liu, Shuangyou
    Wu, Tong
    Gao, Zhiyong
    Liu, Zhaoli
    Zhang, Yue
    Qu, Xiaomin
    Zhang, Yanlei
    Liu, Shaohui
    Ling, Zhuojun
    Lin, Yuehui
    Zhao, Yongqiang
    Song, Yanzhi
    Tan, Xiyou
    Zhang, Yan
    Li, Zhihui
    Yin, Zhichao
    Chen, Bingzhen
    Yu, Xinjian
    Yan, Ju
    Zheng, Qinlong
    Zhou, Xuan
    Gao, Jin
    Chang, Alex H.
    Feng, Xiaoming
    Tong, Chunrong
    LEUKEMIA, 2019, 33 (12) : 2854 - 2866
  • [9] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Sining Liu
    Xinyue Zhang
    Haiping Dai
    Wei Cui
    Jia Yin
    Zheng Li
    Xiao Yang
    Chunxiu Yang
    Shengli Xue
    Huiying Qiu
    Miao Miao
    Suning Chen
    Zhengming Jin
    Chengcheng Fu
    Caixia Li
    Aining Sun
    Yue Han
    Ying Wang
    Lei Yu
    Depei Wu
    Qingya Cui
    Xiaowen Tang
    Blood Cancer Journal, 13
  • [10] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu, Sining
    Zhang, Xinyue
    Dai, Haiping
    Cui, Wei
    Yin, Jia
    Li, Zheng
    Yang, Xiao
    Yang, Chunxiu
    Xue, Shengli
    Qiu, Huiying
    Miao, Miao
    Chen, Suning
    Jin, Zhengming
    Fu, Chengcheng
    Li, Caixia
    Sun, Aining
    Han, Yue
    Wang, Ying
    Yu, Lei
    Wu, Depei
    Cui, Qingya
    Tang, Xiaowen
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345